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DOI: http://dx.doi.org/10.1016/j.hemonc.2013.09.005Over expression of B7-H1 (also named PDL-1 or CD 274) molecule in cancer has been linked to
worse prognosis and resistance to anti-cancer therapies in several malignancies. In this review, we
update on the expression of B7-H1 molecule in solid and hematological malignancies. We also
describe the possible mechanisms by which this molecule inhibits/downregulates the immune
response to cancer cells. Finally, we highlight current and future potential therapeutic strategies that
can be further developed to target this molecule.HThe immune system can identify and controlnascent tumor cells through a process namedcancer immunosurveillance.1 This process
has been the subject of studies in both animal models
and cancer patients. However, cancer immunotherapy
has so far only shown modest clinical beneﬁts for pa-
tients with cancer. This is due to the fact that the im-
mune system can promote tumor progression through
chronic inﬂammation, immunoselection of poorly
immunogenic variants, and by suppressing antitumor
immunity.1,2 B7 homolog 1 (B7-H1), also known as
programmed death ligand-1 (PDL-1) or CD274, is
an inhibitory molecule of T cells that has been impli-
cated in the protection of tumor cells from immune
attack.3 B7-H1 expression, and its association with
clinicopathological, prognostic and immunological
factors, has been reported in several human malignan-
cies including breast,4–9 ovarian,8–11 cervical,12
oral,13–15 head and neck,16,17 brain,18–22 lung,8,9,23–
25 nasopharyngeal,26,27 esophageal,28,29 gastric,30 li-
ver,31–36 colorectal,8,9,37,38 pancreatic,39–44 renal,45–
50 urothelial,51–53 skin,9,54–57 and blood cancers.8,58–
70 Overexpression of this molecule has been linked
to worse prognosis and resistance to anti-cancer ther-
apies in many of these malignancies (Table S1). The
B7-H1 molecule binds to its receptor, programmedematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.comdeath 1 (PD-1) on tumor speciﬁc T cells, which leads
to their apoptosis, and thus shields the tumor cells
from lysis by activated T cells.71 Cancer cells also re-
lease immunosuppressive cytokines such as trans-
forming growth factor beta (TGF-b), Interferon
gamma (IFN-c), and Fas ligand that upregulate B7-
H1 expression and further aid the tumor cells to elude
immune responses.72 Further, blocking of B7-H1 or
its receptor PD-1 with monoclonal antibodies has
been demonstrated to trigger anti-tumor immune re-
sponses, and enhance the effectiveness of anti-cancer
immunotherapy.73 Targeting this molecule can there-
fore lead to a major breakthrough in cancer treatment.
This review illustrates the expression and pathological
correlations of the B7-H1 molecule in human cancers,
its role in carcinogenesis, and its possible therapeutic
targeting strategies to enhance the anti-tumor im-
mune response in malignancies.EXPRESSION OF B7-H1 IN HUMAN
CANCERS
B7-H1 expression in solid tumors
Lung cancer
The B7-H1 expression was ﬁrst demonstrated by
Konishi et al.24 in 2004 in frozen tissue specimens1
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of 52 (100%) patients with non small cell lung carci-
nomas (NSCLC). Both adenocarcinomas and squa-
mous cell carcinomas expressed this molecule. The
expression was observed both in the membrane and
the cytoplasm of tumor cells in a scattered fashion.
However, its expression was not associated with the
clinicopathological factors or the survival of the pa-
tients. The density of tumor-inﬁltrating lymphocytes
(TILs) was inversely correlated to the B7-H1 positive
tumor sites in ﬁve patients. Later, Mu et al. (2011)25
reported the expression of B7-H1 in 58 of 109 (53%)
parafﬁn-embedded specimens of NSCLC patients.
B7-H1 positive cells were signiﬁcantly abundant in
adenocarcinomas than in squamous cell carcinomas
of the lung. The expression was correlated with sur-
vival of less than three years after lobectomy.25
Very recently, Boland et al.23 demonstrated
expression in 42 of 214 (20%) parafﬁn-embedded
specimens of squamous NSCLC patients. B7-H1 in
the tumors was predominantly expressed in the cell
membrane and minimally in the cytoplasm. The
expression, however, was not signiﬁcantly correlated
with the clinical outcomes.23 Further studies, prefera-
bly on frozen specimens are required to conﬁrm the
lower expression of B7-H1 in squamous NSCLC.Gastric carcinoma
B7-H1 expression in gastric carcinoma patients was
reported by Wu et al. (2006).30 The expression was
detected in parafﬁn-embedded sections of 43 of 102
(42%) gastric carcinoma patients. The expression
was signiﬁcantly associated with tumor size, tumor
depth invasion, lymph node metastasis, and reduced
survival. B7-H1 was shown to be a signiﬁcant prog-
nostic factor30 in gastric carcinoma patients.Hepatocellular carcinoma (HCC)
In 2009, Gao et al.32 studied B7-H1 expression in
parafﬁn-embedded specimens of 204 hepatocellular
carcinoma (HCC) subjects. Intratumoral B7-H1
expression was an independent prognostic factor for
disease free survival. Relapse risk was two times more
likely for B7-H1 positive patients after resection sur-
gery compared with B7-H1 negative subjects. B7-H1
positive patients had signiﬁcantly poor disease free
survival and overall survival than B7-H1 negative pa-
tients. B7-H1 positive subjects had more tumors with
vascular invasion. The expression was positively corre-
lated with Forkhead box P3 (Foxp3) positive regula-
tory TILs (Tregs).32 an immunoregulatory T cell
population known to downregulate the immune re-
sponse in cancer.HeIn parallel with the Gao et al. study, Wu et al.35
reported elevated B7-H1 expression in 35 of 71
(49%) HCC cases. Patients with elevated B7-H1
expression had signiﬁcantly poor survival compared
with low expression subjects.35
In 2011, Geng et al.33 studied B7-H1 expression
in 60 HCC cases. Elevated B7-H1 mRNA and pro-
tein expression levels were detected in all HCC sam-
ples. The expression was positively correlated with the
upregulation of Interleukin-10 (IL-10) in tumor
cells,33 an immunoregulatory cytokine known to
downregulate the immune response in cancer. In par-
allel with this study, Wang et al.34 reported B7-H1
expression in 24 of 26 (93%) frozen HCC tissue sam-
ples. The B7-H1 expression was signiﬁcantly associ-
ated with the earlier tumor stage. However, no
signiﬁcant correlation was found between B7-H1
expression and the tumor grade.34
Recently, Chen et al.31 demonstrated high grade
B7-H1 expression in 29 of 63 (46%) HCC cases.
The expression was detected in both the membrane
and cytoplasm of the tumor cells. High B7-H1
expression was signiﬁcantly associated with the inﬁl-
tration of tumor-associated macrophages,31 a cell pop-
ulation known to downregulate the immune response
in cancer.
Intrahepatic Cholangiocarcinoma (ICC)
Intrahepatic cholangiocarcinoma (ICC) is a primary
malignancy of liver that arises from the bile duct epi-
thelium. It is the second most common cancer of the
liver after HCC.36 Ye et al.36 reported B7-H1 expres-
sion in parafﬁn-embedded specimens from 31 of 31
(100%) ICC patients. B7-H1 expression was signiﬁ-
cantly higher in ICC cells than in the adjacent tissue.
Elevated B7-H1 expression was associated with poor
histological differentiation and advanced tumor-no-
dal-metastatic (TNM) stage. The density of CD8+
TILs (a cytotoxic T cell population known to elimi-
nate cancer cells) was inversely correlated with intra-
tumoral B7-H1 expression. Apoptotic CD4+ and
CD8+ TILs count was higher in the cases with ele-
vated B7-H1 expression compared with the cases of
lower expression. The difference, however, did not
reach statistical signiﬁcance.36
Colon cancer
Overexpression of B7-H1 molecule has been impli-
cated in the immune escape of several human malig-
nancies, including colorectal carcinoma.9,37,38 Dong
et al.9 were the ﬁrst to detect the B7-H1 presence
via immunohistochemical analysis in 10 of 19 (53%)
frozen samples of colon cancer patients.matol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.com
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In 2005, Xiao et al.38 detected B7-H1 molecule in
TILs via in situ hybridization on parafﬁn-embedded
colorectal carcinoma samples. Signiﬁcantly more ele-
vated expression levels of this molecule were observed
in the tumor cells than in TILs. Metastasis of colorec-
tal carcinoma was correlated with an increase in the
expression level of B7-H1 in both tumor cells and
TILs. Moreover, the expression in TILs was signiﬁ-
cantly associated with the degree and depth of tumor
invasion. The study concluded that B7-H1 overex-
pression could be involved in the apoptosis of TILs
in colorectal carcinoma patients and thus promote im-
mune escape of tumor cells.38
Hua et al.37 reported high B7-H1 expression in 15
of 33 (45%) cases of colorectal carcinoma. There was
a signiﬁcant inverse correlation between B7-H1
expression and CD3+ TILs density in the tumor nest
and the tumor stroma. The densities of CD4+/
Foxp3+ and CD8+/Foxp3+ Tregs in B7-H1 high
group were signiﬁcantly higher than those of the
B7-H1 low group. Other clinicopathological factors
were not determined.37
Pancreatic cancer
The B7-H1 expression was demonstrated in pancre-
atic cancer patients for the ﬁrst time by Nomi et al.
in 2007.43 The expression was detected in 20 of 51
(39%) frozen tumor samples. The B7-H1 status was
determined to be a signiﬁcant independent prognostic
factor. B7-H1 positive patients had signiﬁcantly worse
survival rates compared with B7-H1 negative patients.
B7-H1 expression had a signiﬁcant inverse correlation
with CD4+ TILs and CD8+ TILs. However, no sig-
niﬁcant correlation was found between B7-H1 and tu-
mor, nodal, metastatic statuses, and pathologic stage.43
Geng et al.40 reported B7-H1 expression in paraf-
ﬁn-embedded tumor samples of 40 pancreatic cancer
patients. The expression was predominantly observed
in the cytoplasm of tumor cells. B7-H1 expression
was signiﬁcantly higher in pancreatic carcinoma tis-
sues than in the normal tissue. Positive B7-H1 status
was signiﬁcantly associated with advanced tumor stage
and poor tumor differentiation. However, the expres-
sion did not correlate with the size of the tumor. A
positive correlation was demonstrated between intra-
tumoral B7-H1 overexpression and IL-10 level at
both the mRNA and protein levels.40
Loos et al.42 also demonstrated B7-H1 expression
in parafﬁn-embedded tumor samples. B7-H1 expres-
sion was detected in pancreatic cancer cells, tumor-
surrounding tubular complexes, pancreatic islet cells,
TILs, and endothelial cells. The expression in pancre-
atic cancer cells was signiﬁcantly correlated with post-Hematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.comoperative survival. B7-H1 positive status was also
associated with the increased prevalence of Foxp3+
TILs Tregs compared to B7-H1 negative tumors.
However, it did not reach statistical signiﬁcance
(P = 0.06).42
Later in 2009, Huang et al.41 also reported ele-
vated expression levels of B7-H1 in tissues of 60.5%
patients with pancreatic carcinoma. No signiﬁcant
expression was observed in normal samples. B7-H1
positive status was signiﬁcantly associated with IL-
10 level in tumor tissues. Similarly, Chen et al.39
determined B7-H1 expression in 18 of 40 (45%) pan-
creatic cancer patients. B7-H1 expression was signiﬁ-
cantly correlated with advanced tumor stage, and was
demonstrated to be an independent poor prognostic
factor.39
A year later, Wang et al.44 reported signiﬁcantly
higher B7-H1 expression in pancreatic carcinoma tis-
sues than in normal samples. B7-H1 expression was
signiﬁcantly correlated with tumor pathological grade,
and it was a prognostic indicator of poor disease-spe-
ciﬁc survival. All of these studies indicate a possible
role of B7-H1 in immune escape of pancreatic cancer
cells.44
Ovarian cancer
B7-H1 has been implicated in the immune evasion of
various tumors, including ovarian cancer.8–11 In 2007,
Hamanishi et al.11 investigated the expression of B7-
H1 in parafﬁn-embedded specimens of 70 ovarian
cancer patients. Their study revealed that elevated
B7-H1 expression levels were associated with poor
prognosis. The overall survival rate of ﬁve years in
high B7-H1 expression patients was signiﬁcantly
worse than in those who had a lower B7-H1 expres-
sion. Moreover, the progression-free survival rate of
high expression patients was signiﬁcantly lower com-
pared to patients with lower expressions of this mol-
ecule. Multivariate analysis concluded that B7-H1 was
an independent poor prognostic factor for both pro-
gression-free and overall survival of ovarian cancer
patients.11
Breast cancer
Breast cancer is the leading cause of cancer related
deaths in women.74,75 The ﬁrst study demonstrating
the presence of B7-H1 molecule expression in breast
cancer patients was documented by Ghebeh et al.
(2006).4 The correlation of this molecule with the
clinicopathological status of the malignancy was inves-
tigated in frozen tumor samples of 44 breast cancer
patients.4 B7-H1 expression (membranous and/or
cytoplasmic) was detected in the tumor cells and/or3
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TILs of 50% of breast cancer patients. The expression
was totally absent in healthy tissue areas of the af-
fected breast. B7-H1 expression was found to be sig-
niﬁcantly correlated with bad prognostic factors
including large tumor size, histology grade III tumors,
negative estrogen receptors, negative progesterone
receptors, and human epidermal growth factor recep-
tor 2 (Her2/neu) negative status.4 A year later, these
ﬁndings were further conﬁrmed by the same group in
their follow-up study of 69 breast cancer patients.5
B7-H1 expression was also demonstrated to be asso-
ciated with the proliferative potential of the tumor
cells.5 The B7-H1 expression was signiﬁcantly corre-
lated with the Ki-67 proliferative marker and a high
mitotic index. Most tumor cells simultaneously re-
vealed expression of B7-H1 and nuclear expression
of Ki-67.5 Moreover, the association of B7-H1 posi-
tive TILs with Foxp3+ Tregs in the tumor microen-
vironment was investigated by Ghebeh et al. (2008).6
B7-H1 expression in TILs within the tumor environ-
ment was signiﬁcantly correlated with the presence of
Foxp3+ Tregs6 In their subsequent investigation in
2010, Ghebeh et al.,7 demonstrated that doxorubicin
was able to downregulate the B7-H1 cell surface
expression and to upregulate its nuclear expression
in breast cancer cells. Blockade of B7-H1 via small
interfering ribonucleic acid (siRNA) led to signiﬁ-
cantly enhanced apoptosis in 90% of the breast cancer
cells. Furthermore, Akt pathway inhibition and doxo-
rubicin treatment synergistically lowered both the cell
surface and nuclear expression of B7-H1 molecule in
the tumor cells.7 These studies therefore suggest that
immunotherapeutic targeting of PD-L1/PD-1 path-
way in breast cancer patients in conjunction with
the available therapeutic modalities can facilitate the
effectiveness of other anti-tumor treatment
strategies.76
Cervical carcinoma
Cervical cancer is the second most common malig-
nancy reported in women (after breast cancer) around
the globe.77–81 In 2009, Karim et al.12 reported intra-
tumoral B7-H1 cell surface expression in parafﬁn-
embedded sections of 22 of 115 (19%) cervical cancer
patients. The expression was signiﬁcantly associated
with increased intraepithelial inﬁltration by Foxp3+
T cells (P = 0.022). However, it did not correlate
with the survival of the patients.12 This lower per-
centage of B7-H1 positive cervical cancer patients
and its negative correlation with survival can be attrib-
uted to the fact that 51 patients in the study had al-
ready received post-operative radiotherapy. Further
studies on frozen specimens and untreated patientsHeare required to investigate the correlation of B7-H1
expression with the prognostic factors of the disease.
Squamous cell carcinomas of the head and neck
(SCCHN)
Head and neck carcinomas account for 5% of all can-
cers, and over 90% of them are squamous cell carcino-
mas.82 In 2003, Strome et al.17 demonstrated B7-H1
expression in 16/24 (66%) frozen tumor samples of
squamous cell carcinomas of the head and neck
(SCCHN) patients. Both intracytoplasmic and mem-
brane expressions were observed. Clinical and prog-
nostic correlations were not determined in this
study.17 Later in 2013, Lyford-Pike et al.16 reported
B7-H1 expression in 14/20 (70%) parafﬁn-embedded
specimens of human papilloma virus-associated head
and neck squamous cell carcinomas (HPV-SCCHN).
Cell surface expression was observed in cancer cells at
the tumor periphery and CD68+ tumor-associated
macrophages. However, the clinical and prognostic
correlations were not determined.16
B7-H1 expression in oral squamous cell carcino-
mas (OSCC) was studied by Malaspina et al.14 and
Cho et al.13 In 2011, Malaspina et al.14 reported
expression in 38/39 (97%) frozen tumor samples of
OSCC patients. B7-H1 expression was highly ex-
pressed in CD14+ TILs.14 In a similar study, Cho
et al.13 demonstrated expression in 39 of 45 (87%)
parafﬁn-embedded specimens of OSCC subjects.
The expression was both membranous and cytoplas-
mic in the tumor cells. Tumor-associated ﬁbroblasts
were also found to be positive for B7-H1 expression
in 18 of 45 (40%) patients. Its expression by the tu-
mor cells did not affect the survival of OSCC patients.
However, it was signiﬁcantly correlated with less dif-
ferentiated OSCC cells. A decrease in the number of
TILs in the tumor environment was also correlated
with the expression of B7-H1. However, the B7-
H1+ tumor-associated ﬁbroblasts had no impact on
the clinical parameters of the patients.13
Nasopharyngeal carcinoma (NPC)
NPC is the third most common malignancy of East
Asia with the incidence of 15–50 cases per 100,
000 population.83 B7-H1 expression has been investi-
gated in nasopharyngeal carcinomas (NPCs).26,27 In
2008, Zhang et al.27 reported expression in 40 of
59 (68%) NPC patients. The expression was signiﬁ-
cantly correlated with advanced tumor stage and lym-
phatic metastasis.27 Later, Hsu et al.26 demonstrated
expression in parafﬁn-embedded tumor samples of
NPC patients. However, the expression was not asso-
ciated with the clinical outcomes of the patients. Thismatol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.com
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might be due to the fact that all 28 patients involved
in the study had already completed curative chemo/
radiotherapy.26 Further studies of untreated patients
are required to conﬁrm the clinicopathological signif-
icance of B7-H1 in NPCs.
Esophageal cancer
Esophageal cancers are the seventh leading cause of
cancer related mortalities in the US, with a ﬁve-year
survival rate of merely 17%.84 In 2005, Ohigashi
et al.29 reported B7-H1 expression in 18 of 41
(44%) frozen specimens of squamous esophageal can-
cer patients. The expression was observed both in the
membrane and the cytoplasm of the tumor cells. The
overall survival of B7-H1 positive patients was signif-
icantly worse than that of B7-H1 negative patients.
B7-H1 status was a highly signiﬁcant independent
prognostic factor.29
B7-H1 expression has also been reported in Bar-
rett’s carcinoma (adenocarcinoma of the distal esoph-
agus).28 Barrett’s carcinoma is one of the most
aggressive malignancies and arises from intestinal
metaplasia.28 In 2011, Loos et al.28 demonstrated
B7-H1 expression in parafﬁn-embedded specimens
of 74 of 101 (73%) Barrett’s carcinoma patients. It
was abundantly expressed in the tumor and the TILs
cell membrane and cytoplasm. Elevated intratumoral
B7-H1 expression was signiﬁcantly associated with
advanced tumor size and invasiveness, as well as in-
creased risk of mortality from cancer. A high expres-
sion of B7-H1 was also associated with a twofold
lower median prevalence of TILs (0.32 versus 0.67).
However, the correlation was not statistically signiﬁ-
cant (P = 0.06).28
Urothelial cancer
Urothelial cancer is the second most common malig-
nancy of the genitourinary tract.85 The disease is the
second most common cause of deaths related to gen-
itourinary tumors.85
In 2007, Inman et al.52 reported B7-H1 expression
in parafﬁn-embedded specimens of 79 of 280 (28%)
urothelial cancer patients. The expression was de-
tected in the plasma membrane of the tumor cells.
B7-H1 was signiﬁcantly associated with advanced
grade tumors. The expression of B7-H1 was also a
signiﬁcant determinant of the status of tumor stage
progression.52
In the same year, Nakanishi et al.53 demonstrated
B7-H1 expression in the frozen tumor samples of pa-
tients with urothelial cancer. Focal pattern expression
was detected in the membrane and the cytoplasm of
cancer cells. B7-H1 was signiﬁcantly correlated withHematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.comthe tumor grade, and was notably associated with pri-
mary tumor classiﬁcation. Elevated B7-H1 expression
was signiﬁcantly associated with poor survival com-
pared with low grade B7-H1 expression. Postopera-
tive tumor recurrence was also signiﬁcantly
associated with higher B7-H1 expression.53
In 2008, Boorjian et al.51 detected B7-H1 expres-
sion in 39 of 314 (12%) parafﬁn-embedded tumor
samples. Predominant membrane and occasional cyto-
plasmic expression were observed in the tumor cells.
The expression was signiﬁcantly related to advanced
disease stage at cystectomy. Considerably elevated
B7-H1 expression was observed in tumors with great-
er number of PD-1 positive TILs. The expression was
a signiﬁcant predictor of mortality after cystectomy.
Subjects with organ conﬁned B7-H1 positive tumors
were three times more likely to die after cystectomy
than B7-H1 negative patients.51
Later, Wang et al.86 reported B7-H1 expression in
36 of 50 (72%) parafﬁn-embedded tumor samples.
B7-H1 expression was signiﬁcantly associated with
the tumor grade and the clinical stage of the disease.
B7-H1 positive patients had signiﬁcantly poorer sur-
vival than B7-H1 negative subjects. Furthermore,
the expression of B7-H1 molecule was demonstrated
to be an independent prognostic factor of urothelial
cancer of the bladder.86
Renal cell carcinoma (RCC)
Renal cell carcinoma (RCC) is the thirteenth most
common cancer worldwide.87 The disease is usually
asymptomatic during early stage but is highly meta-
static. In 2004, Thompson et al.47 reported B7-H1
expression in 130 of 196 (66%) frozen RCC samples.
Expression was detected both in tumor cells and
TILs. High intratumoral B7-H1 expression was sig-
niﬁcantly associated with adverse pathological features
that included higher nuclear grade, regional lymph
node involvement, histological tumor necrosis, and
distant metastasis. Patients with elevated B7-H1
expression levels (either in TILs or tumors) were
4.5 times more likely to die from RCC than patients
who had lower B7-H1 expression.47
In 2005, the same group investigated B7-H1
expression in 17 of 26 (65%) frozen metastatic
RCC tumor samples.48 Expression was detected in tu-
mor cells and TILs. High B7-H1 expression (in tu-
mors and/or TILs) was signiﬁcantly associated with
increased risk of death.48
In their 2006 study, Thompson et al. demon-
strated B7-H1 expression in 73 of 306 (24%) paraf-
ﬁn-embedded RCC tumor samples.49 B7-H1
expression was signiﬁcantly associated with adverse5
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pathological features including advanced tumor-no-
dal-metastatic (TNM) stage, increase in tumor size,
high nuclear grade, and coagulative tumor necrosis.
B7-H1 positive patients were four times more likely
to die from RCC than B7-H1 negative patients.
The expression was signiﬁcantly associated with met-
astatic progression.49
The following year, Krambeck et al.46 reported on
the expression of B7-H1 in 70 of 298 (24%) parafﬁn-
embedded specimens of RCC. B7-H1 positive pa-
tients were four times more likely to die from RCC
than B7-H1 negative patients. The expression was
independently associated with death from RCC.46
Wilms’ tumor (nephroblastoma)
Wilms’ tumor or nephroblastoma is the second most
common renal malignancy of childhood.88 In 2008,
Routh et al.89 demonstrated B7-H1 expression in
11 of 81 (14%) parafﬁn-embedded Wilms’ tumor
specimens. Intratumoral B7-H1 expression was asso-
ciated with a threefold increased risk of recurrence.
However, this association did not reach statistical sig-
niﬁcance (P = 0.057). Nonetheless, patients with B7-
H1 positive favorable tumor histology were at signif-
icantly increased risk of disease recurrence
(P = 0.027) than subjects with B7-H1 negative favor-
able tumor histology.89
Melanoma
Melanoma is the deadliest malignancy among skin
cancers. It is responsible for 50,000 deaths each year
worldwide, and its incidence is still rising.90 Advanced
stage patients have a median survival of one year only.
The available treatments prolong the lives of patients
but do not completely cure the disease.90,91
In 2010, Hino et al.55 reported high B7-H1
expression in 34 of 59 (58%) parafﬁn embedded mel-
anoma specimens. Tumor thickness was signiﬁcantly
higher in the high expression group than in the lower
expression group. Advanced tumor stage had signiﬁ-
cantly more elevated B7-H1 expression than in those
with less advanced tumors. Patients with lymph node
metastasis had a signiﬁcantly higher B7-H1 expres-
sion than patients without lymph node metastasis. Pa-
tients with high B7-H1 expression also had
signiﬁcantly lower overall survival than the lower
expression patient group, thus indicating that B7-
H1 expression was an independent predictor of over-
all survival.55
Similarly, Gadiot et al.54 reported B7-H1 expres-
sion in parafﬁn-embedded specimens of 63 melanoma
patients. Higher frequency of B7-H1 positive staining
was detected in satellite metastases (25%), and in in-Hetransit metastases (40%). B7-H1 expression was
shown to increase with disease progression.54
Recently, Taube et al.56 demonstrated B7-H1
expression in 57 of 150 (38%) parafﬁn-embedded
melanoma patients. The study found 98% of B7-H1
positive samples were highly associated with TILs
compared to 28% of the B7-H1 negative cases. B7-
H1 expression was signiﬁcantly associated with
inﬂammatory inﬁltrates. Clinicopathological factors,
including tumor thickness and TNM stage, were
not associated with B7-H1 expression. Further, B7-
H1 expression in metastatic melanoma patients corre-
lated with signiﬁcantly improved survival. This result
can, however, be misleading because 43% of the met-
astatic melanoma patients involved in the study had
already received systemic immunotherapy, including
high dose interleukin-2 (IL-2), IFN-a, anti-PD-1
monoclonal antibody/vaccine, or combinations of
these agents.56 Further studies (preferably on frozen
samples) of untreated patients are required to investi-
gate the possible role of B7-H1 in the immune escape
of melanoma cells and in the overall survival of mela-
noma patients.
Brain tumors
Brain tumors account for 2% of all the malignancies.19
The most common brain tumors are meningiomas
and gliomas.19 In 2003, Wintterle et al.21 reported
B7-H1 expression in glioma patients. The expression
was detected in 10 of 10 (100%) frozen tumor samples
of glioma patients. More than 50% of the cells in 50–
90% of the tumor samples expressed B7-H1.21 Two
years later, Wilmotte et al.20 demonstrated B7-H1
expression in 46 of 54 (85%) frozen glioma samples.
Signiﬁcantly intense B7-H1 staining, with more than
30% positively stained cells, was detected in 18 of 33
samples of high grade anaplastic astrocytoma and glio-
blastoma compared with diffuse astrocytoma and oligo-
dendroglioma samples. B7-H1 expression was therefore
correlated with tumor grade.20
In 2009, Yao et al.22 detected B7-H1 expression in
36 of 48 (75%) frozen glioma samples. The expression
was signiﬁcantly higher in advanced grade gliomas
than in low grade tumors. Intratumoral B7-H1
expression was negatively correlated with the number
of cytotoxic CD8+ T cells.22 Similarly, Jacobs et al.19
reported B7-H1 expression in 51of 83 (61%) parafﬁn-
embedded brain tumor samples (meningiomas, glio-
mas, adenomas and schwanomas). Later, Avril et al.18
demonstrated B7-H1 expression in 10 of 20 (50%)
parafﬁn-embedded tumor samples. However, the clin-
icopathological correlations of B7-H1 were not deter-
mined in these studies.18matol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.com
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Thymic neoplasms (thymomas)
Thymomas are tumors that originate from the thy-
mus, and have a worse prognosis at advanced stages.92
B7-H1 expression in thymomas was detected by
Brown et al. (2003).8 Ten out of 15 (67%) samples
of benign thymoma, 11 of 11 (100%) samples of inva-
sive thymoma, and 7 of 8 (88%) samples of thymic
carcinomas were B7-H1 positive. Overall, 82% of
the total 34 samples showed B7-H1 expression. Clin-
icopathological correlations were not determined.8
B7-H1 expression in hematological malignancies
Lymphomas
Lymphomas are the malignancies of B/T lympho-
cytes. Lymphomas account for 55.6% of all blood can-
cers.93 B7-H1 expression has been reported in the
following lymphomas:
Peripheral T cell lymphoma (PTCL). Peripheral T cell
lymphoma (PTCL) is the most common form of T
cell lymphoma, and is aggressive. It is a sub-type of
non-Hodgkin’s lymphoma (NHL).94 In 2003, Brown
et al.8 detected B7-H1 via immunohistochemical analy-
sis of 7 of 11 (64%) samples of PTCL. In 2009, Wilcox
et al.59 reported B7-H1 expression in 22 of 144 (15%)
PTCL samples using immunohistochemical analysis.
The expression was detected in tumor cells and mono-
cytes. However, the clinicopathological associations of
B7-H1 were not determined in these studies.
Cutaneous T cell lymphoma (CTCL). Cutaneous T cell
lymphoma (CTCL) is a subtype of NHL that pre-
sents in the skin.95 In 2009, Wilcox et al.59 demon-
strated B7-H1 expression in 3 of 11 (27%) parafﬁn-
embedded specimens of CTCL. The expression was
detected in tumor cells and monocytes. The clinico-
pathological associations of B7-H1 were not
determined.59
Adult T-cell lymphoma (ATL). Adult T-cell lymphoma
(ATL) is a rare but highly aggressive subtype of
NHL.96 In 2009, Kozako et al.58 demonstrated in-
creased B7-H1 expression in 5 of 23 (22%) cases of
ATL patients. B7-H1 expression was detected in
CD4+/CD25+ T cells. No expression was observed
in de novo ATL patients. However, more than 10%
CD4+/CD25+ T cells of the 22% ATL patients
showed the expression one year after diagnosis. No
clinicopathological correlations of B7-H1 were
investigated.58
Diffuse large B cell lymphomas (DLBLC). Diffuse large B
cell lymphomas (DLBLC) is the most common type
of NHL among adults,97 and is aggressive. It has anHematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.comannual incidence of seven to eight cases per year.97
In 2011, Andorsky et al.98 reported B7-H1 expres-
sion in 9 of 33 (27%) frozen samples via immunohis-
tochemical analysis. Clinicopathological signiﬁcance of
B7-H1 was not determined in this study.98
Leukemia
Leukemia is the eleventh most common cause of can-
cer-related deaths worldwide.99 The expression of the
B7-H1 molecule and its clinicopathological correla-
tions have been studied in both acute and chronic leu-
kemias.60–68 In 2006, Salih et al.60 reported B7-H1
expression in a cohort of patients with acute myeloid
leukemia (AML), chronic myeloid leukemia (CML),
acute lymphoblastic leukemia (ALL) and chronic lym-
phoblastic leukemia (CLL). Overall, 17 of 30 (57%)
cases were B7-H1 positive.60
A year later, Li et al.61 investigated B7-H1 expres-
sion in 59 AML/ALL patients. The expression was
signiﬁcantly high in relapsed patients, and newly diag-
nosed patients had lower levels of B7-H1 expression
than normal controls. Furthermore, the expression
was signiﬁcantly higher in non-complete remission
patients after therapy than in patients with complete
remission. B7-H1 was correlated with response to
therapy.61 The following year, Chen et al.62 reported
B7-H1 expression in 25 of 60 (42%) AML/ALL pa-
tients. Signiﬁcantly higher expression was detected in
relapsed AML patients than in the newly diagnosed
subjects. B7-H1 positive AML subjects had signiﬁ-
cantly reduced survival compared to B7-H1 negative
subjects. B7-H1 proved to be an independent prog-
nostic factor. Immunotherapeutic efﬁcacy was signiﬁ-
cantly reduced in B7-H1 positive patients than in B7-
H1 negative subjects. Moreover, B7-H1 was signiﬁ-
cantly upregulated in patients following
immunotherapy.62
In 2009, Ge et al.64 detected B7-H1 expression in
42 of 42 (100%) AML patients. More than 5% of
AML cells were B7-H1 positive in 18 of 42 (43%)
of leukemia samples. The expression was signiﬁcantly
higher in the leukemic cells of AML patients than in
the bone marrow mononuclear cells of healthy volun-
teers.64 In 2010, Berthon et al.65 reported high B7-
H1 expression in 14 of 79 (18%) of AML patients.
Spontaneous expression was signiﬁcantly increased
in 5 of 9 (56%) of relapsed patients.65
In 2012, Sun et al.67 studied B7-H1 expression in
50 AML patients. The expression was lower in de
novo AML patients than in the healthy volunteers.
However, it was highest in the relapsed patients.
B7-H1 expression before therapy was signiﬁcantly
higher in non-cytogenetic remission patients than in7
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patients in complete remission. B7-H1 gene expres-
sion was therefore correlated with response to ther-
apy.67 In the same year, Li et al.63 studied B7-H1
expression in 74 AML/ALL patients. The expression
was signiﬁcantly higher in non-complete remission
patients after therapy compared with patients in com-
plete remission. B7-H1 gene expression was corre-
lated with response to therapy.63
Grzywnowicz et al.68 demonstrated B7-H1 expres-
sion in 44 of 44 (100%) of CLL patients. B7-H1
expression was signiﬁcantly higher in CLL patients
than in the peripheral blood/bone marrow mononu-
clear cells of healthy volunteers. The expression was
signiﬁcantly higher in tyrosine kinase zeta-associated
protein (ZAP-70) positive subjects compared with
ZAP-70 negative patients.68 These studies suggest a
possible role of B7-H1 in the immune escape of leu-
kemic cells and its association with response to
therapy.
Multiple myeloma (MM)
Multiple myeloma (MM) is the second most common
hematological malignancy in the western world after
NHL, and accounts for 10% of all blood cancers.100
In 2007, Liu et al.72 detected B7-H1 expression in a
majority of 82 MM patients. The expression was sig-
niﬁcantly higher in plasma cells in MM patients than
in non-MM subjects. Very recently, Tamura et al.70
reported B7-H1 expression in 10 of 40 (25%) MM
cases. The expression was signiﬁcantly associated with
increased serum lactate dehydrogenase levels and the
percentage of myeloma cells in the bone marrow. Fur-
thermore, the expression of B7-H1 tended to be high-
er in advanced stage patients. However, its association
did not reach statistical signiﬁcance. B7-H1 expres-
sion was upregulated in patients who relapsed or be-
came resistant to anti-MM therapy.70MECHANISM OF B7-H1 MEDIATED
TUMOR CELL IMMUNE RESISTANCE
B7-H1 is a member of the B7 family of immunoreg-
ulatory molecules.4,101 It is a surface glycoprotein
known to be expressed on conventional CD4+ and
CD8+ T cells, dendritic cells (DCs), macrophages,
B cells, Tregs, epithelial cells, endothelial cells, im-
mune privileged sites such maternal-fetal barrier,4,101
and on a majority of tumor cells (Table S1). Both
co-stimulatory and co-inhibitory characteristics of
B7-H1 molecule have been reported.102–104 The
inhibitory behavior of B7-H1 molecule is attributed
to its binding with a co-inhibitory receptor, PD-1,
also known as CD 279.9,105 PD-1 is expressed onHeTregs, B cells, antigen-activated CD4+ and CD8+
T cells, natural killer (NK) cells, and frequently on
TILs.106 In contrast, the stimulatory role of B7-H1
has been ascribed to its binding with yet unidentiﬁed,
co-stimulatory non-PD-1 receptors.9,103
Classical mechanism of adaptive immune response
activation
Dendritic cells (DCs) are the most pivotal of antigen
presenting cells (APCs) that initiate immune
responses.107 Immature DCs express major histocom-
patibility complex class-II (MHC-II) and other co-
stimulatory molecules, and reside in non-lymphoid
tissues.108 DCs upregulate MHC-II molecules on
their cell surfaces and migrate to the lymphoid tissues
upon stimulation with foreign invaders or other dan-
ger-associated molecules. At this stage, they may
encounter naïve T cells.108 Activation of naïve
CD4+ T helper cells requires the linkage of the T cell
receptor (TCR) with antigen loaded MHC-class II
complex on mature DCs, while the activation of
CD8+ cytotoxic T lymphocytes (CTLs) requires
the binding of the TCR with antigen-loaded major
histocompatibility complex class-I (MHC-class I)
complex on APCs.109 This is known as Signal 1.109
Following Signal 1, another co-stimulatory signal is
required for the T cells to induce an effective immune
response and thereafter the induction of apoptosis in
the target cell.110 CD28 is the principal co-stimula-
tory receptor expressed on both CD4+ T helper
and CD8+ CTLs.110,111 Successful simultaneous gen-
eration of Signal 1 and binding of CD28 to their co-
stimulatory ligands, B7-1 (also known as CD80) or
B7-2 (also known as CD86), on DCs/APCs gener-
ates Signal 2.112 This second signal stimulates T cells
by reducing the threshold of TCR signaling, which is
accomplished by the formation of immunological syn-
apse, triggering IL-2 production and upregulation of
Bcl-X2 anti-apoptotic protein which protects T cells
from apoptosis.113,114 Subsequent proliferation of T
cells and their secretion of cytokines and cytolytic
molecules, such as perforin and granzyme, cause tu-
mor/target cell death112 (Fig. 1A).
B7-H1 upregulation and dampening of immune
responses
Absence of Signal 2 renders T cells anergic.114 Persis-
tent antigen presentation leads to upregulation of PD-
1 on T cells, which is followed by the expression of
B7-H1 on APCs in the local tissue.115 Subsequent
B7-H1/PD-1 interaction inhibits TCR signaling by
recruiting the Src homology region 2 domain contain-
ing phosphatases 1 and 2 (SHP-1, SHP-2).116 Thesematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.com
Fig. 1. Comparison of the effective classical immune response against tumor-derived antigens versus the tumoral B7-H1 mediated immune escape. (A) Classical immune
response against tumor-derived antigens and tumor cell lysis. (1) Tumor antigens released by the tumor cells are captured by antigen presenting cells (APCs) and processed to
small peptides for their presentation by the major histocompatibility complex (MHC) molecule. The T cell is activated through linkage of T cell receptor (TCR) with MHC-antigen
complex (Signal 1).109 A co-stimulatory signal (Signal 2: B7/CD28 interaction) is also required to initiate an effective anti-tumor immune response by the T cells. (2) This causes
the T cells to release cytotoxic compounds (such as granzymes/perforin) that attack (3) and disrupt the plasma membrane of tumor cells, causing tumor cell death/lysis.112–117
(B) Failure of T cell to launch an effective anti-tumor immune response. (1) Absence of Signal 2 leads to prolonged antigen presentation.114,115 (2) Consistent presentation of the
antigen causes upregulation of PD-1 on T cells followed by the (3) release of inflammatory cytokines, activation of signal transducer and activator of transcription (STATs)
pathways and subsequent upregulation of B7-H1 on the tumor cells. (4) Loss of phosphatase and tensin homolog (PTEN) activates the phosphatidylinositide 3-kinase/Akt (PI3-K/
Akt) and mammalian target of rapamycin (mTOR) pathways which also lead to the upregulation of B7-H1 on the tumor cells. (5) B7-H1 and PD-1 over expression and their
interaction cause T cell exhaustion/anergy and/or apoptosis, thus enabling the tumor cells to effectively evade the immune system113–119.
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interaction of APCs/DCs with T cells.117 This over-
expression and interaction of inhibitory molecules
causes exhaustion and/or apoptosis of T cells by
impairing their metabolism, inhibiting the release of
Bcl-X2 anti-apoptotic protein,113,114 impairing effec-
tor cytokine production (such as IL-2 and IFN- c)
and T cell proliferation.115,118,119 The B7-H1/PD-1
axis has also been demonstrated to increase the num-
ber of Foxp3+ Tregs in the local tissue environ-
ment,120 which further inhibits the immune
response by contributing to the suppression of pro-
duction of effector cytokines and proliferation of
effector T cells.121,122 It has been demonstrated that
B7/ mice are deprived of the ability to produce
Tregs.6,123 Blockade of B7-H1 has been shown to
prevent Treg-mediated immune regulation,124 indi-Hematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.comcating the crucial role of B7-H1 in the generation
and immunoregulatory function of Tregs. Moreover,
Amarnath et al.125 have shown that B7-H1/PD-1
interaction is also responsible for converting human
T helper 1 (Th1) cells to Tregs in vivo, and prevents
the onset of human to mouse xenogeneic graft versus
host disease (xGVHD). Blockade of the B7-H1/PD-
1 pathway or inhibition of SHP-1/SHP-2 was shown
to restore Th1 differentiation and to induce
xGVHD.125
It has been observed that tumor sites are often
loaded with TILs.126 Logically, this should aid the im-
mune system in the clearance of tumor cells. Indeed,
in ovarian127 and gastric cancer128 patients, the inﬁl-
tration of T cells, myeloid DCs, and NKs has been
associated with a better prognosis. However, this fac-
tor has also been associated with a poor prognosis in9
10
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B7-H1 positive RCC patients.129 Furthermore, the
B7-H1 positive status is linked to tumor metastasis
and increased risk of mortality in RCC subjects.49,129
B7-H1 expression could thus be responsible for the
association of TILs with poor prognosis as tumor
cells might exploit the B7-H1 expression to overcome
anti-tumor immune responses mediated by TILs.126
Mechanisms of B7-H1 upregulation by tumor cells
The expression of B7-H1 by tumor cells depends on
two kinds of mechanisms: innate and adaptive immune
resistance.130 Innate resistance corresponds to B7-H1
upregulation by oncogenic signaling pathways in the
tumor cells.130 For example, phosphatase and tensin
homolog (PTEN) loss in breast cancer cells131 and
gliomas132 activates phosphatidylinositide 3-kinase/
Akt (PI3K/Akt) and phosphatidylinositide 3-kinase/
mammalian target of rapamycin (PI3K/mTOR) path-
ways which subsequently result in B7-H1 overexpres-
sion. Likewise, anaplastic lymphokinase signaling in
lymphomas and lung cancer upregulates B7-H1 via sig-
nal transducer and activator of transcription 3 (STAT
3) signaling.133 Toll-like receptor 4 has also been re-
ported to upregulate B7-H1 expression on macrophages
by lysophosphatidylserine-dependent signal transducer
and activator of transcription 1 (STAT 1) signaling
mechanism134,135 (Fig. 1B).
Adaptive immune resistance refers to the exploita-
tion of PD-1 ligand; B7-H1 by tumor cells to evade
endogenous immune response.130 B7-H1 is normally
expressed to protect a tissue from immune attack.
However, cancer cells exploit it to protect themselves
from cytolysis.130 The adaptive immune resistance of
tumor cells can be ascribed to the observation that
B7-H1 expression is often induced by interferons,
mainly IFN-c.136–138 Although IFN-c is known for
its role in the defense against viral infections, it has
been shown to upregulate B7-H1 expression in
non-lymphoid tissues.139,140 IFN-c plays an immuno-
suppressive role by inducing the expression of the
transcription factor, interferon regulatory factor 1
(IRF-1). IRF-1 then binds to the promoter region
of B7-H1 gene and leads to its expression141
(Fig. 1B). B7-H1 upregulation has been observed at
inﬂammatory sites in the encephalomyelitis model,142
and in muscle biopsies from inﬂammatory myopathy
patients.143 Recently, Taube et al.56 have reported a
signiﬁcant correlation of B7-H1 expression in mela-
noma cells with IFN-c expression in the tumor
microenvironment. Thus, the beneﬁt of IFN-c in
the autoimmune setting, and its role in tumor im-
mune tolerance might be attributed in part to the
upregulation of B7-H1 at inﬂammatory sites, whichHesubverts immune responses by B7-H1/PD-1
interaction.TARGETING THE B7-H1 MOLECULE
B7-H1 blockade by anti-B7-H1 monoclonal
antibody and soluble recombinant peptide
Antibodies that target tumor cell-associated B7-H1
block its engagement with the PD-1 receptor on T
cells. This allows CTLs to launch an effective immune
response against the B7-H1 positive tumor
cells.130,144 Moreover, anti-B7-H1 monoclonal anti-
bodies (mAbs) could likely lead to tumor cell death
by the NK cell mediated-antibody dependent cell
cytotoxicity (ADCC) pathway.145 In this pathway,
the Fc receptor of NK cells binds with the Fc domain
of the tumor cell bound anti-B7-H1 mAb, resulting in
tumor cell lysis through the production of effector
cytokines (such as IFN-c, IL-2) and cytotoxic gran-
ules145 (Table 1).
Very recently, Brahmer et al.146 examined the
safety and efﬁcacy of BMS-936559, a human B7-
H1 speciﬁc IgG4 mAb in a Phase I clinical trial.
The study involved 207 patients with cancers that in-
cluded melanoma, RCC, NSCLC, ovarian, pancreatic,
gastric and breast cancers in advanced stages. Objec-
tive responses were reported in 2 of 17 RCC, 5 of
49 NSCLC, 9 of 52 melanoma, and 1 of 17 ovarian
cancer patients. No response was observed in any of
the patients with B7-H1 negative tumors; however,
6–17% of the patients showed durable tumor regres-
sions. Prolonged disease stabilization was observed in
12–41% of the patients with advanced melanoma, and
with RCC and NSCLC patients at six months’ fol-
low-up. Importantly, none of the patients developed
pneumonitis and the rate of treatment-related grade
3–4 adverse events were 9%.146 Conversely, 3% cases
of pneumonitis and 14% grade 3–4 adverse events
were reported on an anti-PD1 clinical trial by Topa-
lian et al.147 This could be partly explained by the fact
that B7-H1 blockade spares B7-DC, a molecule
which is expressed only in a minority of human can-
cers.145 B7-DC blockade in mice has been reported to
excessively increase T helper cell 2 (Th2) immune re-
sponse, exacerbating inﬂammation of respiratory
tract.148 Hyperactivation of Th2 cells is also associ-
ated with increased production of interleukin 4 (IL-
4) which is known to dampen Th1 immune
response.145,148,149 B7-DC sparing could thus prevent
the onset of severe toxic inﬂammation, lower the
occurrence of anti-B7-H1 mAb-related adverse
events, and prevent a decline in Th1 activity against
the tumor cells.matol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.com
Table 1. Suggested potential therapeutic strategies that inhibit B7-H1 expression in tumors.
Agent/
intervention
Pathway targeted/mechanism Effect on tumor microenvironment Reference
Anti-B7-H1
mAb
ADCC B7-H1/PD-1 interaction blockade; prevents regulatory T cell recruitment
and CTL apoptosis, induces tumor regression and prolongs disease
stabilization in patients with advanced cancers
Hirano et al. (2005)73, Brahmer
et al. (2012)146
Sinomenine Unknown Prevents induction of B7-H1 surface expression in TECs Chen et al. (2005)104
Triptolide Inhibits NF-jB transcription Prevents induction of B7-H1 surface expression Chen et al. (2006)174, Liang et al.
(2008)153
Honokiol Inhibits PI3K/mTOR pathway Downregulates B7-H1 surface expression; decreases number of regulatory
T cells
Crane et al. (2009)132
Nimesulide Unknown COX-2/PGE2 independent pathway Prevents induction of B7-H1 surface expression; induces tumor cell
apoptosis and inhibits tumor cell proliferation
Liang et al. (2009)191
sPD-1-CH50 Binds to B7-H1 and blocks its interaction with
PD-1
Increases cytotoxic activity of macrophages and CTLs against B7-H1
positive tumor cells
Qiu et al. (2009)150
Doxorubicin Akt dependent pathway dominant in nucleus, and
unknown Akt independent pathway dominant in
cell surface
Downregulates cell surface B7-H1 expression by translocation to the
nucleus
Ghebeh et al. (2010)7
siRNAs B7-H1 cell surface knockdown B7-H1 nuclear
knockdown
Enhances effector functions and proliferation of CD4 and CD8 positive
human T cells Significantly enhances doxorubicin mediated tumor cell
apoptosis
Hobo et al. (2010,2013)193,194,
Iwamura et al. (2012)192, Ghebeh
et al. (2010)7
Abbreviations: Anti-B7-H1 mAb = Anti-B7-H1 monoclonal antibody; ADCC = Antibody Dependent Cell-Mediated Cytotoxicity pathway; CTL = Cytotoxic T lymphocyte; TECs = Renal tubular epithelial cells; NF-jB = Nuclear factor-
kappa light chain enhancer of activated B cells; PI3K/mTOR = Phosphatidylinositide 3-kinase/mammalian target of rapamycin pathway; COX-2/PGE2 = Cyclooxygenase 2/Prostaglandin- E2 pathway; sPD-1-CH50 = Soluble
programmed death 1 recombinant peptide with CH50 fibronectin domain; siRNAs = Small interfering RNA.
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1 in conjunction with CH50 ﬁbronectin domain
(sPD-1-CH50) is known to bind to B7-H1 and inhi-
bit its interaction with the PD-1 in a murine hepa-
toma model.150 This strategy has been shown to
enhance the recruitment and cytotoxic activity of T
cells/macrophages against B7-H1 positive tumor cells
and to increase the production of effector T cell cyto-
kines (Table 1). The sPD-1-CH50 treatment was
also shown to inhibit the growth and metastasis of
the tumor cells in vivo.150 Blockade of B7-H1 by
anti-B7-H1 mAbs and sPD-1-CH50 therefore has a
potential therapeutic signiﬁcance for the inhibition
of growth and invasion of tumors, as well as the accel-
eration of anti-tumor immunity.
B7-H1 suppression by chemotherapeutic drugs
Chemotherapeutic drugs are designed to treat cancers
by inducing apoptosis and inhibiting proliferation of
tumor cells.151 They include anthracyclines (e.g.
doxorubicin, danorubicin), alkaloids (e.g. doxetaxcel,Hematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.comsinonemine), alkylating agents (e.g. cisplatin), and
pyrimidine antagonist (e.g. arabinofuranosyl cytidine;
Ara-C). However, these drugs may also have immu-
nomodulatory properties.7,152,153 Doxorubicin, an
anthracycline-based drug used in the treatment of
breast cancer,154 and childhood soft tissue sarcomas
and lymphomas,155,156 is reported to stimulate the
production of cytokines,157 CTL158 and NK cell im-
mune responses,157 enhance differentiation of macro-
phages,159 and downregulate cell surface B7-H1
expression in breast cancer cells.7 Nevertheless, doxo-
rubicin upregulates B7-H1 nuclear expression via Akt
dependent pathway in tumor cells which renders them
anti-apoptotic.7 This is because nuclear translocation
of B7-H1 molecule can permit its interaction with the
apoptotic machinery of the tumor cell.7 Administra-
tion of doxorubicin in conjunction with siRNA-med-
iated B7-H1 knockdown has been shown to augment
doxorubicin-mediated tumor cell apoptosis.7
A combination of chemotherapy with B7-H1 tar-
geting can therefore be beneﬁcial in overcoming11
12
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drug-mediated immune resistance of tumor cells and
enhancing anti-tumor immunity.
Sinomenine, an alkaloid extracted from a Chinese
medicinal plant Sinomenium acutum,160 is well known
in the Far East for the treatment of rheumatoid
arthritis,160–162 autoimmune nephritis,163,164 renal
allograft rejection,165 and hepatitis.165 Sinomenine
has been widely recognized for its immunosuppressive
and anti-inﬂammatory properties,104 and has recently
been demonstrated to possess anti-tumoral properties
as well.104 Sinomenine-mediated downregulation of
B7-H1 mRNA and protein expression of IFN-c
and tumor necrosis factor alpha (TNF-a) treated re-
nal tubular epithelial cells (TECs) has been reported
by Chen et al.104 TECs with B7-H1 overexpression
were seen to inhibit cytotoxic cytokine production
by T cells in TEC: T cell co-cultures, and sinomenine
treatments resulted in signiﬁcantly enhanced effector
cytokine production by the T cells (Table 1). The
drug could thus be a feasible option for the treatment
of RCC.104
Triptolide, an oxygenated diterpene compound ex-
tracted from a Chinese medicinal herb, Tripterygium
wilfordii, has been widely used in the Far East for
the treatment of autoimmune diseases such as rheu-
matoid arthritis, and tumors.166,167 Triptolide has
been shown to induce tumor cell apoptosis both
in vitro and in vivo168–170 (Table 1). Moreover, remis-
sion rates of 87% in granulocytic leukemia and 71% in
mononucleocytic leukemia have been reported in Tri-
ptolide clinical trials in China.171 The anti-tumor
property of this compound has been ascribed to its
ability to activate caspase-3 and caspase-8,172 and ren-
der tumor cells more susceptible to topoisomerase
inhibitors173 (Table 1). Triptolide enhances doxoru-
bicin-mediated apoptosis of tumor cells,168 and down-
regulates B7-H1 expression in TNF-a regulated
TECs by decreasing transcription of nuclear factor-
kappa light chain enhancer of activated B cells (NF-
jB).174 B7-H1 inhibition by triptolide could thus
partly explain its anti-tumoral behavior.
Honokiol, a natural dietary product extracted from
the seed cones of Magnolia grandiﬂora, attenuates tu-
mor growth in breast,175,176 gastric,177,178
colon,179,180 pancreatic,181 and skin cancers.182 Hon-
okiol inhibits transcription of NF-jB175 and the
(PI3K/mTOR) pathway,176 both of which are impli-
cated in the upregulation of B7-H1 expression174
(Table 1). Indeed, honokiol has been demonstrated
to downregulate B7-H1 expression in PTEN deﬁ-
cient glioma, breast, and prostate cancer cells.132
Honokiol can therefore be an appealing therapeutic
option in overcoming cancer cell immune resistance.HeCyclooxygenase 2 (COX-2) is an enzyme which
catalyses the conversion of arachidonic acid to prosta-
glandins (PG-E2).183 Over expression of COX-2 has
been implicated in inﬂammation and reported in a
number of human cancers including lung, breast, skin,
prostate and colon cancers.183 Nimesulide is a selec-
tive COX-2 inhibitor, and is known to inhibit prolif-
eration of tumor cells and induce tumor cell apoptosis
in vitro,184,185 as well as prevent metastasis in vivo.186–
188 Nonetheless, it has been suggested that COX-2
independent mechanisms are involved in nimesulide-
mediated anti-tumor responses.189–191 Liang et al.191
reported the downregulation of B7-H1 expression in
IFN-c treated human breast cancer cells. They
showed that COX-2 inhibitors other than nimesulide
(NS-398 and meloxican) fail to inhibit B7-H1 expres-
sion. Furthermore, addition of PG-E2 to IFN-c trea-
ted breast cancer cells did not inhibit nimesulide-
mediated B7-H1 downregulation, which indicated
that COX-2/PG-E2 independent mechanisms might
be involved191 (Table 1). Inhibition of B7-H1 by
nimesulide can therefore be a potential therapeutic
strategy to boost anti-tumor immune responses.
Tumor speciﬁc B7-H1 gene silencing by siRNA
siRNA-mediated gene silencing in conjunction with
adoptive T cell therapy using tumor speciﬁc T cells
provide an opportunity to speciﬁcally target tumor
cells192 (Table 1). Iwamura et al.192 reported on the
generation of CD8+ T cell clones which recognize a
tumor antigen speciﬁc MAGE-A4-derived peptide.
TCR-a and b genes from these CD8+ T cell clones
were isolated and transduced retrovirally into human
T cells, which expressed B7-H1 upon stimulation
with the MAG-A4 positive tumor antigen. In this,
the siRNA-mediated knockdown of the B7-H1 mol-
ecule is shown to augment the cytotoxic activity of the
tumor speciﬁc T cells.192
DC-based vaccines are being explored to boost
immunity in patients with chronic viral infections
and cancer. However, limited clinical beneﬁts have
been observed, suggesting the need to improve the po-
tency of DC-based vaccines.193 Hobo et al.194 investi-
gated enhanced cytotoxic cytokine production (IFN-
c, IL-2, IL-5, TNF-a) by minor histocompatibility
antigen (MiHA)-speciﬁc CD8+ T cells and memory
cells of relapsed leukemia patients upon stimulation
with siRNA-mediated B7-H1 knockdown DCs in
T cell: DC co-culture experiments. This strategy also
augmented the production of granzyme B by antigen
experienced CTLs and increased their proliferative
capacity.194 In their recent study, Hobo et al.193 dem-
onstrated the development of enhanced clinical gradematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.com
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DC vaccine by lipidoid nanoparticle-mediated trans-
fection of DCs with B7-H1 siRNA. The B7-H1 si-
lenced DCs effectively enhanced ex vivo antigen-
speciﬁc CD8+ T cell responses from transplanted leu-
kemia and lymphoma patients.193
B7-H1 siRNA treatment of breast cancer cells has
also been shown to enhance doxorubicin-mediated
apoptosis by knocking down nuclear B7-H1 expres-
sion.7 [See Section 4: Targeting the B7-H1 molecule].
These ﬁndings suggest that siRNA-mediated silenc-
ing of B7-H1 gene can be utilized to boost anti-tumor
immunity in conjunction with tumor-speciﬁc adoptive
T cell therapy and chemotherapy to augment the efﬁ-
cacy of anti-tumor vaccines.
CONCLUSION
Cancer cells exploit the co-inhibitory B7-H1 molecule
to evade the immune system. Overexpression of B7-
H1 molecule has been linked to worse prognosis
and poor response to anti-cancer therapeutic strate-
gies in several human malignancies. Targeting B7-
H1 expression can open the inhibitory gate and ren-
der many tumor cell types susceptible to lysis/apopto-
sis, therefore killing many birds with one stone. ThisHematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.comstrategy may improve the efﬁcacy of standard available
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B7-H1: B7 homolog 1
PDL-1: programmed death ligand-1
PD-1: PD -1
TGF-b: transforming growth factor beta
IFN-c: interferon gamma
NSCLC: non small cell lung carcinomas
TILs: tumor inﬁltrating lymphocytes
HCC: hepatocellular carcinoma




Tregs: regulatory T cells
Her2/neu: human epidermal growth factor
receptor 2
siRNA: small interfering RNA
HPV: human papilloma virus
CTLs: cytotoxic T lymphocytes
SCCHN: squamous cell carcinomas of the
head and neck
OSCC: oral squamous cell carcinomas
NPC: nasopharyngeal carcinoma
RCC: renal cell carcinoma
PTCL: peripheral T cell lymphoma
NHL: non-Hodgkin’s lymphoma
CTCL: cutaneous T cell lymphoma
ATL: adult T-cell lymphoma
DLBLC: diffuse large B cell lymphomashemoncstem.edmgr.comAML: acute myeloid leukemia
CML: chronic myeloid leukemia
ALL: acute lymphatic leukemia
CLL: chronic lymphatic leukemia




APCs: antigen presenting cells
MHC-II: major histocompatibility complex
class II
TCR: T cell receptor
MHC-class I: major histocompatibility com-
plex class I
SHP-1/ SHP-2: Src homology region 2 do-
main containing phosphatase 1/2
Th 1: T helper 1 cells
xGVHD: xenogeneic graft versus host
disease
NKs: natural killer cells
PTEN: phosphatase and tensin homolog
PI3K: phosphatidylinositide 3-kinase
mTOR: mammalian target of rapamycin
STAT: signal transducer and activator of
transcription
anti-B7-H1 mAb: anti-B7-H1 monoclonal
antibody
ADCC: antibody dependent cell cytotoxicity
Th 2: T helper 2 cells
sPD-1-CH50: soluble programmed death 1
recombinant peptide in conjunction
with CH50 ﬁbronectin domain
TNF-a: tumor necrosis factor alpha
TECs: renal tubular epithelial cells
NF-jB: nuclear factor-kappa light chain en-
hancer of activated B cells
COX-2: cyclooxygenase 2
PG-E2: prostaglandin E2
MiHA: minor histocompatibility antigen17
